The Financial Times leads on AstraZeneca's decision to scrap plans for a new vaccine manufacturing plant in Liverpool, calling it "a blow to the government's growth agenda". The paper says executives have warned that policies pursued by the government will make the UK a less attractive place to invest.

AstraZeneca is pulling out of its plans to build a £450mn UK vaccine manufacturing plant after months of wrangling with British officials about state investment for the Merseyside project, in a major blow to Prime Minister Sir Keir Starmer’s government.

Pharmaceutical company AstraZeneca has cancelled a planned 450 million-pound investment in a vaccine manufacturing plant in northwest England.

AstraZeneca has cancelled plans for a £450m vaccine manufacturing plant in Liverpool, blaming a cut in funding from government.

The pharmaceutical giant said it was no longer pursuing a £450 million investment in a vaccine manufacturing plant in Merseyside after discussions with the Government

AstraZeneca has axed plans to invest £450 million in a vaccine manufacturing plant in Merseyside in a fresh blow to Labour’s mission for growth.

AstraZeneca announced it will not proceed with plans for a 450 million pound vaccine manufacturing plant in Speke, Liverpool. The decision was influenced by discussions with the current government and changes in the financial offer.

AstraZeneca is no longer pursuing plans for a 450 million pound ($558.32 million) vaccine manufacturing plant in Speke, Liverpool, a company spokesperson said on Friday.

AstraZeneca has axed plans to build a £450million vaccine manufacturing plant because of a lack of Government support in the latest blow to Rachel Reeves. The Labour government last summer tried to reduce the amount of state support provided to the Liverpool project from about £90million to £40million,